HOWL

Werewolf Therapeutics Inc. (HOWL) | Rumor.io

Werewolf Therapeutics

HOWL

Attention (50-day avg)0%

Attention rank (50-day avg)#842

Bullish sentiment (50-day avg)79%

Price to earnings ratio-0.7

Market capitalization45.2M

Earnings per share-0.73

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-60.8M

Social

What share of all stock conversation is about HOWL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 26

HOWL is gaining momentum, with some users predicting a short squeeze and a price increase to $3.00 or more.
The company's Phase 3 development is a positive factor, with one user calling it a "great buy" and another predicting a price increase to $1.50.
The sudden availability of 4.4M shares is seen as a sign of shorts running for cover, with one user stating "this looks like shorts running for cover" and another predicting a price increase to over $2.00.

Generated by AI

Sentiment

Of the messages about HOWL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +21.56	74.24% -13.63
Bearish	—	—	0% -21.56	25.76% +13.63

Bullish· Aug 24

$HOWL is expected to reach $1.50 with a strong bull run ahead.
The stock's Phase 3 is expected to bring significant upside, with some analysts predicting a 200-300%+ run.
$HOWL is expected to break through the $1 mark and reach $3 or more, with some analysts predicting it will reach $2-3 by the end of the week.

Bearish· Aug 21

The stock's price is expected to drop below $0.50 when it opens.
Shorting the stock is considered a good opportunity, with some users even calling it "almost free".
The stock's price has already broken through a key support level of $0.75, and users are expecting it to continue falling.

Generated by AI

Topics

Of the messages about HOWL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	60.5%
Technical Analysis	—	—	100%	26.96%
Analysts	—	—	0%	8.46%
Earnings	—	—	0%	3.45%
Controversies	—	—	0%	0.63%
Macro	—	—	0%	0%

Analysts· May 25

Analysts at Jefferies initiate coverage on Werewolf Therapeutics with a Buy rating and a price target of $22.
Analysts at HC Wainwright initiate coverage on Werewolf Therapeutics with a Buy rating and a price target of $32.
Analysts at Evercore ISI Group initiate coverage on Werewolf Therapeutics with an Outperform rating and a price target of $23.

Announcements· Aug 21

Werewolf Therapeutics (HOWL) is merging with Ambros Therapeutics, with the combined company to focus on advancing neridronate for CRPS-1, a painful orphan disease with no FDA-approved treatment.
The merger is accompanied by an oversubscribed $150 million private placement, led by RA Capital Management and Janus Henderson Investors, with a syndicate of institutional investors participating.
The combined company is expected to have a cash runway into 1H 2029, including through Phase 3 topline and proof-of-concept data for neridronate, and will be renamed Ambros Therapeutics.

Generated by AI

Community

Of the messages about HOWL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	15.09%	17.89%
Newcomers	—	—	84.91%	82.11%

Regulars· Aug 21

The merger agreement between Werewolf Therapeutics and Ambros Therapeutics has led to a $150 million private placement, and the company is setting up a strong base.
The stock is forming a tight chart and the bears are asking for a reversal, with some participants calling for a break of the high of the day.
The acquisition of Werewolf Therapeutics has been valued at approximately $1 per share, and some participants are congratulating the long-term holders on their bet, with one participant selling the stock at $1.05 per share.

Newcomers· Aug 26

Newcomers to the HOWL asset are excited about its potential for a massive short squeeze, with some thinking it could reach $3.
There is a sense of community and encouragement among these newcomers, with calls to "hodl" (hold on to the asset) and "let's go" in support of HOWL's upward momentum.
Some newcomers are paying attention to institutional investor activity, noting a pattern of steady accumulation and suggesting that this could be worth keeping an eye on for further potential gains.

Generated by AI

News

1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost

A merger and a $150 million capital infusion is giving Werewolf's next chapter more firepower, but investors still face risks.

1mo agoYahoo Finance

Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News

Werewolf Therapeutics stock explodes higher on a merger agreement with Ambros Therapeutics. But is there any further upside left in HOWL shares?

1mo agoYahoo Finance

Why Is Werewolf Therapeutics Stock Gaining Friday? - Werewolf Therapeutics (NASDAQ:HOWL)

1mo agoBenzinga

Also Discussed

Investors talking about HOWL also mention

#	Name	Attention
1	TScan Therapeutics, Inc.TCRX	0%0
2	Trevi Therapeutics, Inc.TRVI	0%new
3	MDVL - MedAvail Holdings, Inc.	——
4	Momentus Inc. Class A Common StockMNTS	0%+0
5	Sunshine Biopharma Inc.SBFM	0%0
6	GLDN - Nicholas Gold Income ETF	——
7	KMPH - KemPharm, Inc.	——
8	GT Biopharma Inc.GTBP	0%0
9	DYNT - Dynatronics Corporation	——
10	GRIL - Muscle Maker, Inc.	——

Werewolf Therapeutics Inc.

Healthcare
Biotechnology

Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions. The company’s current work centers on its proprietary PREDATOR platform, which is used to create INDUKINE and INDUCER molecules intended to activate selectively in diseased tissue while limiting activity in healthy tissue. Its pipeline includes immune-modulating candidates aimed at solid tumors and specific cancer targets, reflecting a concentration on oncology and immunotherapy. Werewolf Therapeutics Inc. operates as a clinical-stage developer of advanced biologic therapies, with research and development activities spanning tumor-directed immune activation and targeted protein engineering. Headquartered in Watertown, Massachusetts, the company is positioned within the biotechnology sector as a specialist in next-generation cancer therapeutics.

Website

Location

200 Talcott Ave

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about HOWL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 26

HOWL is gaining momentum, with some users predicting a short squeeze and a price increase to $3.00 or more.
The company's Phase 3 development is a positive factor, with one user calling it a "great buy" and another predicting a price increase to $1.50.
The sudden availability of 4.4M shares is seen as a sign of shorts running for cover, with one user stating "this looks like shorts running for cover" and another predicting a price increase to over $2.00.

Generated by AI

Sentiment

Of the messages about HOWL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +21.56	74.24% -13.63
Bearish	—	—	0% -21.56	25.76% +13.63

Bullish· Aug 24

$HOWL is expected to reach $1.50 with a strong bull run ahead.
The stock's Phase 3 is expected to bring significant upside, with some analysts predicting a 200-300%+ run.
$HOWL is expected to break through the $1 mark and reach $3 or more, with some analysts predicting it will reach $2-3 by the end of the week.

Bearish· Aug 21

The stock's price is expected to drop below $0.50 when it opens.
Shorting the stock is considered a good opportunity, with some users even calling it "almost free".
The stock's price has already broken through a key support level of $0.75, and users are expecting it to continue falling.

Generated by AI

Topics

Of the messages about HOWL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	60.5%
Technical Analysis	—	—	100%	26.96%
Analysts	—	—	0%	8.46%
Earnings	—	—	0%	3.45%
Controversies	—	—	0%	0.63%
Macro	—	—	0%	0%

Analysts· May 25

Analysts at Jefferies initiate coverage on Werewolf Therapeutics with a Buy rating and a price target of $22.
Analysts at HC Wainwright initiate coverage on Werewolf Therapeutics with a Buy rating and a price target of $32.
Analysts at Evercore ISI Group initiate coverage on Werewolf Therapeutics with an Outperform rating and a price target of $23.

Announcements· Aug 21

Werewolf Therapeutics (HOWL) is merging with Ambros Therapeutics, with the combined company to focus on advancing neridronate for CRPS-1, a painful orphan disease with no FDA-approved treatment.
The merger is accompanied by an oversubscribed $150 million private placement, led by RA Capital Management and Janus Henderson Investors, with a syndicate of institutional investors participating.
The combined company is expected to have a cash runway into 1H 2029, including through Phase 3 topline and proof-of-concept data for neridronate, and will be renamed Ambros Therapeutics.

Generated by AI

Community

Of the messages about HOWL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	15.09%	17.89%
Newcomers	—	—	84.91%	82.11%

Regulars· Aug 21

The merger agreement between Werewolf Therapeutics and Ambros Therapeutics has led to a $150 million private placement, and the company is setting up a strong base.
The stock is forming a tight chart and the bears are asking for a reversal, with some participants calling for a break of the high of the day.
The acquisition of Werewolf Therapeutics has been valued at approximately $1 per share, and some participants are congratulating the long-term holders on their bet, with one participant selling the stock at $1.05 per share.

Newcomers· Aug 26

Newcomers to the HOWL asset are excited about its potential for a massive short squeeze, with some thinking it could reach $3.
There is a sense of community and encouragement among these newcomers, with calls to "hodl" (hold on to the asset) and "let's go" in support of HOWL's upward momentum.
Some newcomers are paying attention to institutional investor activity, noting a pattern of steady accumulation and suggesting that this could be worth keeping an eye on for further potential gains.

Generated by AI

Werewolf Therapeutics

Social

Aug 26

Bullish· Aug 24

Bearish· Aug 21

Analysts· May 25

Announcements· Aug 21

Regulars· Aug 21

Newcomers· Aug 26

1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost

Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News

12 Health Care Stocks Moving In Friday's Intraday Session

Gold Moves Higher; US Composite PMI Surges In August

Why is Werewolf Therapeutics stock surging more than 100% today?

Why Is Werewolf Therapeutics Stock Gaining Friday? - Werewolf Therapeutics (NASDAQ:HOWL)

Also Discussed

Werewolf Therapeutics Inc.

Company Information

Location

1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost

Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News

12 Health Care Stocks Moving In Friday's Intraday Session

Gold Moves Higher; US Composite PMI Surges In August

Why is Werewolf Therapeutics stock surging more than 100% today?

Why Is Werewolf Therapeutics Stock Gaining Friday? - Werewolf Therapeutics (NASDAQ:HOWL)

Also Discussed

Social

Aug 26

Bullish· Aug 24

Bearish· Aug 21

Analysts· May 25

Announcements· Aug 21

Regulars· Aug 21

Newcomers· Aug 26